POINT PLEASANT, W.Va. — Drug abuse, including the abuse of prescription painkillers, has reached epidemic proportions in the U.S., and no state has been hit harder than West Virginia. Fruth Pharmacy, according to company chairman and president Lynne Fruth, is trying to make a difference in the lives of those in its communities who are
PALATINE, Ill. — Acura Pharmaceuticals Inc. has entered into a licensing pact that grants exclusive U.S. and Canadian marketing rights to its Nexafed and Nexafed Sinus abuse-resistant decongestant products to MainPointe Pharmaceuticals LLC. Acura said Friday that MainPointe will assume all manufacturing and commercialization activities for the two products. The agreement includes an upfront cash
Pharmacists in Indiana are backing state legislation that would uphold over-the-counter access to medicines containing pseudoephedrine (PSE) while reining in illicit use of these products for methamphetamine production. Community Pharmacies of Indiana (CPI) is supporting Indiana Senate Bill 80 (SB80), also known as the Pharmacist Legitimization Bill. CPI said the measure aims to control the sale
POINT PLEASANT, W.Va. — Lynne Fruth, president of Fruth Pharmacy, recently attended an event at the West Virginia State Capitol Building where she was honored for her company’s commitment to help prevent the sale of drugs used in the making of methamphetamine. Earlier this year, Fruth Pharmacy participated in the “Our Children, Our Future” Policy
POINT PLEASANT, W.Va. — Lynne Fruth, President of Fruth Pharmacy, has been honored for her company’s commitment to help prevent the sale of drugs used in the making of methamphetamine, known as “meth.” At the West Virginia State Capitol Building, Fruth participated in the Our Children, Our Future Policy Summit, where she was asked to
PALATINE, Ill. — Acura Pharmaceuticals Inc. has licensed its methamphetamine-resistant pseudoephedrine (PSE) technology to Bayer Healthcare LLC for use in future products. Under the license and development agreement announced Tuesday, Acura will provide an exclusive worldwide license to its Impede technology to Bayer for use in an undisclosed meth-resistant, PSE-containing product and to jointly develop
